The aim of this study was to examine the link between leflunomide (Arava) treatment and lung disease in patients with rheumatoid arthritis. The authors concluded that leflunomide was not associated with increased likelihood of lung disease.

This study assessed the risk of serious infection during treatment with tumor-necrosis factor inhibitors in rheumatoid arthritis patients.

This study investigated whether exposure to tumor necrosis factor alpha (TNFalpha) inhibitors increases the risk of herpes zoster (shingles) in rheumatoid arthritis patients.

This study compared the effectiveness of different biological drugs in patients with rheumatoid arthritis who have already been unresponsive to anti-tumor necrosis factor (TNF) treatment. The authors concluded that a non-TNF biological treatment was more effective at lowering disease activity than taking a second anti-TNF drug. 

This study looked at rheumatoid arthritis (RA) patients’ preferences when choosing either an infused or an injected biological treatment. It also compared patient reported outcomes (PRO) for treatment with adalimumab (Humira) and etanercept (Enbrel).

This study investigated if abatecept has an effect on bone mineral density in patients with rheumatoid arthritis. They found that patients taking abatacept have higher bone mineral density in the head of the femur bone. 

This study investigated the safety and effectiveness of sarilumab (Kevzara) compared to other drugs in rheumatoid arthritis (RA). They found that sarilumab is similarly or more effective than other RA drugs.

This study examined what drug treatment strategy is best for treating patients with early rheumatoid arthritis.

This study investigated the safety and effectiveness of abatacept (Orencia) in combination with other medications to treat rheumatoid arthritis. The study concluded that abatacept in combination with conventional synthetic DMARDs was well tolerated and similarly effective as abatacept and methotrexate.

This study investigated if tocilizumab (TCZ; Actemra) increases cardiovascular (CVD) risk in patients with rheumatoid arthritis (RA).

They found that CVD risk associated with TCZ was similar to other biological drugs.